RxDoctor Payments Data

Neeran Bajouka, MD

Internal Medicine · Farmington Hills, MINPI 1326146390

Payments from drug & device makers

$8,891in general payments, 2019–2025

Across 403 payments — averaging $22.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$3K
  • AstraZeneca$2K
  • Bayer$472
  • Boehringer Ingelheim$454
  • Pfizer$432
  • AbbVie$386
  • plus $3K from 33 others

What the payments were for

  • Food & beverage$8,884100%
  • Education$70%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,891 in reported general payments places this provider in the 90th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$43,695
Medicare patients
138
Services billed
457

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide163$189,964
JardianceEmpagliflozin100$98,583
MounjaroTirzepatide57$63,335
EliquisApixaban45$36,397
JanuviaSitagliptin Phosphate45$35,680
Bydureon BciseExenatide Microspheres19$22,788
RexultiBrexpiprazole12$16,440
LinzessLinaclotide30$16,210
MyrbetriqMirabegron24$15,367
FarxigaDapagliflozin Propanediol12$13,730
JanumetSitagliptin Phos/Metformin Hcl15$13,646
Xigduo XrDapaglifloz Propaned/Metformin15$8,162
Lantus SolostarInsulin Glargine,hum.Rec.Anlog54$6,557
BystolicNebivolol Hcl12$6,241
Losartan Potassium400$4,895

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$2,746$189,964163 claims
Boehringer IngelheimJardiance$454$98,583100 claims
Lilly USA, LLCMounjaro$349$63,33557 claims
MerckJanuvia, Janumet$41$49,32660 claims
PfizerEliquis, Paxlovid$432$37,76757 claims
Otsuka America Pharmaceutical, Inc.Rexulti$69$16,44012 claims
AbbVieLinzess$386$16,21030 claims
Astellas Pharma US IncMyrbetriq$246$15,36724 claims
AstraZenecaFarxiga$1,612$13,73012 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$43$2,559219 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Farmington Hills

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →